Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-12-2008

Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community

Auteurs: Ariane K. Kawata, Dennis A. Revicki

Gepubliceerd in: Quality of Life Research | Uitgave 10/2008

Abstract

Introduction

Symptoms and cognitive impairments of schizophrenia affect social integration and functioning. Accurate measurement is essential in evaluating treatment needs and outcomes. The Personal and Social Performance scale (PSP; Morosini et al. Acta Psychiatrica Scandinavica 101(4):323–329, 2000) is a clinical tool assessing social functioning in rehabilitation settings.

Methods

One hundred and twenty-nine patient/informant dyads at eight US sites participated in this study. Patients were at least 18 years old, have had schizophrenia/schizoaffective disorder for one year or more, and were currently residing in the community. Informants were at least 21 years old, cared for the patient for at least one month, and had contact at least twice weekly. The PSP, Personal Evaluation of Transitions in Treatment (PETiT), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions—Severity (CGI-S), and Quality of Life Scale (QLS) tools were completed. Analyses focused on descriptive statistics, item characteristics, reliability, and validity.

Results

Patients were community-dwelling outpatients without severe difficulties. The PSP scores were well correlated with each other and related measures. Socially useful activities and personal and social relationships were the strongest indicators, suggesting separate aspects of functioning. Internal consistency reliability was adequate (α = 0.76). The PSP was sensitive to differences in social functioning by clinical severity.

Conclusions

The PSP suggested scale reliability and validity among outpatients. Future examination should expand validity analyses and evaluate responsiveness.

vorige artikel Cognitive interviewing in the evaluation of fatigue items: Results from the patient-reported outcomes measurement information system (PROMIS)

volgende artikel Comparative responsiveness and minimal change for the Oxford Elbow Score following surgery

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Meer informatie

National Institute of Mental Health (NIMH). (2007). When someone has schizophrenia. Available online at: http://www.nimh.nih.gov/publicat/schizoph.cfm.

American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Press.

Jablensky, A. (2000). Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience, 250(6), 274–285. doi: 10.1007/s004060070002. PubMedCrossRef

Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8–19. PubMed

Regier, D. A., Narrow, W. E., Rae, D. S., Manderscheid, R. W., Locke, B. Z., & Goodwin, F. K. (1993). The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50(2), 85–94. PubMed

World Health Organization (WHO). (2006). Schizophrenia. Home page at: http://www.who.int/mental_health/management/schizophrenia/en/.

Addington, J., & Addington, D. (2000). Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophrenia Research, 44(1), 47–56. doi: 10.1016/S0920-9964(99)00160-7. PubMedCrossRef

Bell, M. D., & Bryson, G. (2001). Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? Schizophrenia Bulletin, 27(2), 269–279. PubMed

Bryson, G., & Bell, M. D. (2003). Initial and final work performance in schizophrenia: cognitive and symptom predictors. The Journal of Nervous and Mental Disease, 191(2), 87–92. PubMedCrossRef

10.

Bryson, G., Bell, M. D., Kaplan, E., & Greig, T. (1998). The functional consequences of memory impairments on initial work performance in people with schizophrenia. The Journal of Nervous and Mental Disease, 186(10), 610–615. doi: 10.1097/00005053-199810000-00004. PubMedCrossRef

11.

Gaite, L., Vázquez-Barquero, J. L., Borra, C., Ballesteros, J., Schene, A., Welcher, B., et al. (2002). Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatrica Scandinavica, 105(4), 283–292. doi: 10.1034/j.1600-0447.2002.1169.x. PubMedCrossRef

12.

Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophrenia Bulletin, 26(1), 119–136. PubMed

13.

Kasckow, J. W., Twamley, E., Mulchahey, J. J., Carroll, B., Sabai, M., Strakowski, S. M., et al. (2001). Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Research, 103(1), 69–78. doi: 10.1016/S0165-1781(01)00260-8. PubMedCrossRef

14.

McGurk, S. R., Mueser, K. T., Harvey, P. D., LaPuglia, R., & Marder, J. (2003). Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatric Services (Washington, DC), 54(8), 1129–1135. doi: 10.1176/appi.ps.54.8.1129.

15.

Palmer, B. W., Heaton, R. K., Gladsjo, J. A., Evans, J. D., Patterson, T. L., Golshan, S., et al. (2002). Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophrenia Research, 55(3), 205–215. doi: 10.1016/S0920-9964(01)00218-3. PubMedCrossRef

16.

Pinikahana, J., Happell, B., Hope, J., & Keks, N. A. (2002). Quality of life in schizophrenia: a review of the literature from 1995 to 2000. International Journal of Mental Health Nursing, 11(2), 103–111. doi: 10.1046/j.1440-0979.2002.00233.x. PubMedCrossRef

17.

Sharma, T., & Antonova, L. (2003). Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. The Psychiatric Clinics of North America, 26(1), 25–40. doi: 10.1016/S0193-953X(02)00084-9. PubMedCrossRef

18.

Burns, T., & Patrick, D. (2007). Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica, 116(6), 403–418. doi: 10.1111/j.1600-0447.2007.01108.x. PubMedCrossRef

19.

Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica, 101(4), 323–329. PubMed

20.

Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., et al. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research, 93(1–3), 117–130. doi: 10.1016/j.schres.2007.03.003. PubMedCrossRef

21.

Kane, J., Canas, F., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research, 90(1–3), 147–161. doi: 10.1016/j.schres.2006.09.012. PubMedCrossRef

22.

Marder, S. R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., et al. (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry, 62(12), 1363–1370. doi: 10.1016/j.biopsych.2007.01.017. PubMedCrossRef

23.

Gigantesco, A., Vittorielli, M., Pioli, R., Falloon, I. R. H., Rossi, G., & Morosini, P. (2006). The VADO approach in psychiatric rehabilitation: a randomized controlled trial. Psychiatric Services (Washington, DC), 57(12), 1778–1783. doi: 10.1176/appi.ps.57.12.1778.

24.

Bodlund, O., Kullgren, G., Ekselius, L., Lindström, E., & von Knorring, L. (1994). Axis V—Global Assessment of Functioning Scale. Evaluation of a self-report version. Acta Psychiatrica Scandinavica, 90(5), 342–347. doi: 10.1111/j.1600-0447.1994.tb01604.x. PubMedCrossRef

25.

Hall, R. C. (1995). Global assessment of functioning. A modified scale. Psychosomatics, 36(3), 267–275. PubMed

26.

Rhee, C. G., & Kim, Y. H. (2006). The newer assessment tools for functionings and the Personal and Social Performance Scale in patients with schizophrenia. Korean Journal of Psychopharmacology, 17(2), 128–142.

27.

Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T., Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10(3), 388–398. PubMed

28.

Vorunganti, L. N., & Awad, A. G. (2002). Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophrenia Research, 56(1–2), 37–46. doi: 10.1016/S0920-9964(01)00161-X. CrossRef

29.

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. PubMed

30.

Guy, W. (1976). The Clinical Global Impression Scale. In ECDEU assessment manual for psychopharmacology (revised). Rockville, MD: National Institute for Mental Health.

31.

SAS Institute, Inc. (2002–2003). SAS software, Version 9.1. Cary, NC: SAS Institute, Inc.

32.

Cronbach, L. J., & Warrington, W. G. (1951). Time-limit tests: estimating their reliability and degree of speeding. Psychometrika, 16(2), 167–188. doi: 10.1007/BF02289113. PubMedCrossRef

33.

Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials (2nd ed.). New York: Oxford University Press.

34.

Gagnon, D. D., Adriaenssen, I., Nasrallah, H., & Morosini, P. (2006). Reliability, validity, and sensitivity to change of the Personal and Social Performance Scale in patients with stable schizophrenia. Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

Titel: Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community
Auteurs: Ariane K. Kawata
Dennis A. Revicki
Publicatiedatum: 01-12-2008
Uitgeverij: Springer Netherlands
Gepubliceerd in: Quality of Life Research / Uitgave 10/2008
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-008-9400-z

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Introduction

Methods

Results

Conclusions

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Andere artikelen Uitgave 10/2008

Cognitive interviewing in the evaluation of fatigue items: Results from the patient-reported outcomes measurement information system (PROMIS)

The Turkish version of the National Eye Institute Refractive Error Quality of Life Instrument: translation, validity and reliability

Evaluating the effectiveness of using PROs in clinical practice: a role for cluster-randomised trials

Taking PROs and patient-centered care seriously: incremental and disruptive ideas for incorporating PROs in oncology practice

Using patient-reported outcomes in clinical practice: proceedings of an International Society of Quality of Life Research conference

Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder